PASO Automated Template Matching for PVC Ablation

NCT ID: NCT04778696

Last Updated: 2021-03-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

144 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-05

Study Completion Date

2022-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pacemapping is an essential tool during ablation of idiopathic PVC and VT. Automated template matching has been shown to have a significant influence on PVC ablation procedures, but the PASO module of CARTO3 has not been studied in a randomized trial. The Aim of this study is to evaluate the additional benefit of PASO template matching on PVC ablation procedure with regard to procedural parameters and outcome when compared with conventional pace mapping. A total of 144 pts will be randomised in a 1:1 fashion to PVC ablation guided by conventional pacemapping vs PVC ablation guided by PASO pacemapping. Patients will be follow up with Holter-ECG and TTE after 3 and 12 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction / Rationale Premature ventricular contractions (PVC) in the otherwise healthy heart are not associated with increased mortality in the absence of a short coupling interval or a compromised left ventricular function and do not require treatment if asymptomatic . Symptomatic idiopathic PVC or VT on the other hand can burden patients with recurring palpitations, dizziness, dyspnea and possibly syncope in cases of fast VT. A reversible decrease in left ventricular function as a result of a high PVC burden has been reported even in patients with no underlying cardiomyopathy . Radiofrequency Ablation (RFA) is a well-established method to treat idiopathic PVC and VT, and is associated with satisfying long-term results. Pacemapping is an essential tool during ablation of idiopathic PVC and VT. Automated template matching has been shown to have a significant influence on PVC ablation procedures, but the PASO module of CARTO3 has not been studied in a randomized trial.

Aim of the study To evaluate the additional benefit of PASO template matching on PVC ablation procedure with regard to procedural parameters and outcome when compared with conventional pace mapping.

Hypothesis PASO guidance during PVC / VT ablation has a significant impact on outcome after catheter ablation of idiopathic PVC / VT.

Study design This study is planned as a two-center trial. All patients presenting for de novo ablation of idiopathic ventricular arrhythmia will be included and randomized in a 1:1 fashion in this open-label, two-center, randomized controlled trial.

In patients randomized to the PASO / intervention group pacemapping will be guided by automated template matching of the PASO module of CARTO3.

In patients randomized to the conventional / control group conventional pacemapping will be employed.

A 3D electroanatomic geometry including activation mapping will be acquired in all patients using CARTO3. Sedation, catheters and monitoring during and after CA, will not differ from standard clinical practice and will be the same for both groups.

Follow-up after 3 and 12 months will assess PVC burden by Holter ECG, symptoms through a standardized questionnaire and LV function by TTE

Duration and study size Based on prior findings ("Impact of Automated Template Matching during PVC Ablation: Results from a Randomized Controlled Trial" Lüker et al. ESC 2014 poster presentation) 144 pts have to be randomized to detect a significant difference with respect to ablation success at follow-up (alpha 0.05, power 80%).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PVC - Premature Ventricular Complex Cardiomyopathies Heart Failure Ventricular Tachycardia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

1:1 simple randomisation
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
Patients will be masked to treatment arm. Investigator performing statistical analysis and adjudicating outcomes will be masked to treatment arm

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

conventional pace mapping

Conventional PVC pace mapping without visual guidance of PASO

Group Type ACTIVE_COMPARATOR

Conventional Pacemapping

Intervention Type PROCEDURE

without visualisation in 3D mapping

PASO pace mapping

PASO pace mapping with visualisation in CARTO3

Group Type EXPERIMENTAL

PASO Pacemapping

Intervention Type PROCEDURE

Using the PASO pacemapping visualisation module of CARTO3

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Conventional Pacemapping

without visualisation in 3D mapping

Intervention Type PROCEDURE

PASO Pacemapping

Using the PASO pacemapping visualisation module of CARTO3

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Informed, written consent
* ventricular arrhythmia (PVC or VT) with indication for CA

Exclusion Criteria

* Patients under guardianship or with mental disorders / disabilities
* Polymorphic PVC / VT
* ongoing myocardial ischaemia
* pregnancy
* valve replacement that prevents access to the suspected site of PVC origin
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biosense Webster, Inc.

INDUSTRY

Sponsor Role collaborator

Universitätsklinikum Köln

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Cologne

Cologne, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jakob Lüker, MD

Role: primary

+4922147832396

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UKK-PASTPVC-2018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Abbott Ventricular Tachycardia PAS
NCT05839873 ACTIVE_NOT_RECRUITING
Atrial Fibrillation Progression Trial
NCT01570361 TERMINATED PHASE4
The TRAMPOLINE VT Study
NCT05152784 COMPLETED NA